Anlotinib hydrochloride clinical trials
Anlotinib hydrochloride is named as an intervention in 16 current clinical trials in our China and Japan registers. 10 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chia Tai Tianqing Pharmaceutical Group Co., Ltd (7). The most-studied condition is Medullary Thyroid Cancer.
How Anlotinib hydrochloride works
All drug targets →- Vascular endothelial growth factor receptor 2 inhibitor InhibitorTarget: KDR kinase insert domain receptor✓ In ChEMBL and the Guide to Pharmacology
- Vascular endothelial growth factor receptor 3 inhibitor InhibitorTarget: FLT4 fms related receptor tyrosine kinase 4✓ In ChEMBL and the Guide to Pharmacology
- Stem cell growth factor receptor inhibitor InhibitorTarget: KIT KIT proto-oncogene, receptor tyrosine kinaseChEMBL only
- Platelet-derived growth factor receptor beta inhibitor InhibitorTarget: PDGFRB platelet derived growth factor receptor betaChEMBL only
- Alveolar soft part sarcomaPhase 3
- Cervical carcinomaPhase 3
- Clear cell renal carcinomaPhase 3
- Colorectal adenocarcinomaPhase 3
- Colorectal cancerPhase 3
- Endometrial carcinomaPhase 3
- Fallopian tube carcinomaPhase 3
- Hepatocellular carcinomaPhase 3
- LeiomyosarcomaPhase 3
- Nasopharyngeal carcinomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4303201, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9601, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Anlotinib hydrochloride
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Anlotinib hydrochloride
16 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Anlotinib hydrochloride
26 conditionsAll 26 conditions
| Condition (as registered) | Trials |
|---|---|
| Medullary Thyroid Cancer | 1 |
| Thyroid Neoplasms | 1 |
| Renal Cell Carcinoma (RCC) | 1 |
| Non-Small-Cell Lung Cancer | 1 |
| Brain Metastases | 1 |
| Endometrial Cancer | 1 |
| Glioblastoma | 1 |
| Metastatic Pancreatic Ductal Adenocarcinoma | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Esophageal Neoplasms | 1 |
| Esophageal Diseases | 1 |
| Gastrointestinal Neoplasms | 1 |
| Advanced Hepatocellular Carcinoma (HCC) | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Metastatic Colorectal Cancer | 1 |
| Melanoma | 1 |
| Non Small Cell Lung Cancer | 1 |
| Alveolar Soft Part Sarcoma | 1 |
| Sarcoma,Soft Tissue | 1 |
| Extremity | 1 |
| Trunk | 1 |
| Anlotinib | 1 |
| Carcinoma | 1 |
| Gastrointestinal Diseases | 1 |
| Stomach Cancer | 1 |
| Gastroesophageal-junction Cancer | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 16 | 10 |
| Clinical trials in Japan | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Anlotinib hydrochloride trials
How many clinical trials are testing Anlotinib hydrochloride?
16 current trials in our China and Japan registers name Anlotinib hydrochloride as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Anlotinib hydrochloride trials recruiting patients?
Yes. 10 of the 16 trials are recruiting: 10 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Anlotinib hydrochloride clinical trials?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd (7), Tianjin Medical University Cancer Institute and Hospital (1), The First People's Hospital of Lianyungang (1) and Sun Yat-sen University (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anlotinib hydrochloride works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anlotinib hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anlotinib hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.